點(diǎn)擊播放按鈕收聽音頻：


The vaccine for the A/H1N1 influenza produced by the Chinese pharmaceutical company Hualan Biological Engineering, has passed an expert evaluation. Another 9 pharmaceutical companies are now taking part in the clinical test phase.

甲型H1N1流感疫苗日前由中國制藥集團(tuán)華蘭生物制品有限公司開始生產(chǎn)，已經(jīng)通過專家認(rèn)證，另外9家制藥公司正處于臨床測試階段。

It's expected that by the end of this year, A/H1N1 vaccines produced on the mainland will be able to meet the demands of five percent of the country's population.

預(yù)計(jì)截止到本年底，在大陸地區(qū)生產(chǎn)的H1N1疫苗將占到整個(gè)國家藥品需求的5%。

The State Food and Drug Administration, says the vaccines produced by domestic pharmaceutical companies will be stored but not administered to the general public. The health administrator will decide on the release of the vaccine depending on the situation of the epidemic.

國家食品藥品監(jiān)督管理局指出，國內(nèi)制藥公司生產(chǎn)的疫苗將做一定儲備，但是不會對公眾完全開放注射。衛(wèi)生部負(fù)責(zé)人將根據(jù)疫情狀況決定藥品發(fā)放。